top of page
Search

CUSABIO COVID-19 Detection Reagents: A MUST-HAVE for Your Next Big Breakthrough in 2021 Research

Since the COVID-19 pandemic, over two million around the world have died from the virus. To address one of the greatest challenges we are facing, numerous researchers are making unprecedented efforts to fight COVID-19. To support COVID-19 research, CUSABIO has developed a large number of SARS-CoV-2 related reagents, including antibody, protein and ELISA kits. Here we list several most popular products with customers, which will meet needs in diverse COVID-19 research in clinical and research labs.


Spike glycoprotein Proteins

Spike protein is one of the major structural proteins of severe acute respiratory syndrome-coronavirus. It is essential for the interaction of the virons with host cell receptors and subsequent fusion of the viral envelop with host cell membrane to allow infection. Some spike proteins of coronavirus are proteolytically cleaved into two subunits, S1 and S2.[1] The spike protein (S protein) has pivotal roles in viral infection and pathogenesis. With the outbreak of Novel Coronavirus 2019(SARS-CoV-2, 2019-nCoV), the spike protein gets more and more attention. CUSABIO is one of the companies that research and manufacture spike protein related reagents for SARS-CoV-2 research in the world. Now there are 10 recombinant spike proteins for SARS-CoV-2 research added to our spike proteins catalog. They are featured with high purity (most of them greater than 90%), and low endotoxin. The bioactivity of some SARS-CoV-2 Spike proteins has been validated. Except for SARS-CoV-2 (2019-nCoV) Spike proteins, you can also find Spike proteins for other species in the following catalog. Quality is guaranteed. And our technical team will be here to support you. The Features of SARS-CoV-2 Spike Glycoprotein Proteins

  • Diverse Expression Systems and TagsCUSABIO provides five expression systems and multiple tags to meet customers’ different requirements.

  • Most of Spike Glycoprotein are In Stock with Low Endotoxin

  • Most of the Purity>90%

  • Activity Validated in Function ELISA and LSPR Assay

Recombinant Human Novel Coronavirus Spike glycoprotein(S), partial (CSB-MP3324GMY1b1) Functional ELISA. Immobilized SARS-CoV-2-S1-RBD at 2 μg/ml can bind SARS-CoV-2-S Antibody (CSB-RA33245A1GMY), the EC50 of SARS-CoV-2-S1-RBD protein is 27.96 - 33.35 ng/ml. Functional ELISA. Immobilized SARS-CoV-2-S1-RBD at 5 μg/ml can bind human ACE2 (CSB-MP866317HU), the EC50 is 2.785-9.139 ng/ml. SARS-CoV-2 Spike protein RBD captured on COOH chip can bind Human ACE2 protein (CSB-MP866317HU) with an affinity constant of 13.8 nM as detected by LSPR Assay. Recombinant Human Novel Coronavirus Spike glycoprotein(S), partial (CSB-YP3324GMY1) Functional ELISA. Immobilized SARS-CoV-2-S1-RBD at 2 μg/ml can bind SARS-CoV-2-S Antibody (CSB-RA33245A0GMY), the EC50 of SARS-CoV-2-S1-RBD protein is 13.48-19.50 ng/ml Functional ELISA. Immobilized SARS-CoV-2-S1-RBD at 5 μg/ml can bind human ACE2 (CSB-MP866317HU), the EC50 is 31.80 - 44.69 ng/ml SARS-CoV-2 Spike protein RBD captured on COOH chip can bind Human ACE2 protein (CSB-MP866317HU) with an affinity constant of 100 nM as detected by LSPR Assay

  • Keeping Up With the Research Hotspot and Launching S Mutant Proteins with High Quality

Recombinant Human Novel Coronavirus Spike glycoprotein(S) (D614G), partial (CSB-MP3324GMY(M1)) Purity: Greater than 90% as determined by SDS-PAGE (Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel. Functional ELISA. Immobilized SARS-CoV-2-S1 (D614G) at 2 μg/ml can bind human ACE2 (CSB-MP866317HU), the EC50 is 8.236-11.22 ng/ml. Recombinant Human Novel Coronavirus Spike glycoprotein(S) (V367F), partial (CSB-MP3324GMY1(M1)) Purity: Greater than 90% as determined by SDS-PAGE (Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel. Functional ELISA. Immobilized SARS-CoV-2-S1-RBD (V367F) at 5 μg/ml can bind human ACE2 (CSB-MP866317HU), the EC50 is 65.58-90.16 ng/ml. Recombinant Human Novel Coronavirus Spike glycoprotein(S) (G476S), partial (CSB-MP3324GMY1(M4)) Purity: Greater than 90% as determined by SDS-PAGE (Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel. Functional ELISA. Immobilized SARS-CoV-2-S1-RBD (G476S) at 5 μg/ml can bind human ACE2 (CSB-MP866317HU), the EC50 is 47.11-92.3 ng/ml. Send an Inquiry

Spike glycoprotein Proteins Catalog Spike glycoprotein Proteins for Bovine coronavirus (strain vaccine) (BCoV) (BCV) CodeProduct NameSourceCSB-EP333052BJORecombinant Bovine coronavirus Spike glycoprotein(S) ,partialE.coliCSB-YP333052BJORecombinant Bovine coronavirus Spike glycoprotein(S),partialYeastCSB-BP333052BJO CSB-MP333052BJO CSB-EP333052BJO-B Recombinant Bovine coronavirus Spike glycoprotein(S) ,partialBaculovirus Mammalian cell In Vivo Biotinylation in E.coli Spike glycoprotein Proteins for Human coronavirus OC43 (HCoV-OC43) CodeProduct NameSourceCSB-BP336163HIY CSB-MP336163HIY CSB-EP336163HIY-B Recombinant Human coronavirus OC43 Spike glycoprotein(S),partialBaculovirus Mammalian cell In Vivo Biotinylation in E.coli CSB-YP336163HIYRecombinant Human coronavirus OC43 Spike glycoprotein(S),partialYeastCSB-EP336163HIYRecombinant Human coronavirus OC43 Spike glycoprotein(S),partialE.coliSpike glycoprotein Proteins for Human SARS coronavirus (SARS-CoV) (Severe acute respiratory syndrome coronavirus) CodeProduct NameSourceCSB-YP348663HQE CSB-EP348663HQE CSB-BP348663HQE CSB-EP348663HQE-B Recombinant Human SARS coronavirus Spike glycoprotein(S) ,partialYeast E.coli Baculovirus In Vivo Biotinylation in E.coli Spike glycoprotein Proteins for Human coronavirus HKU1 (isolate N5) (HCoV-HKU1) CodeProduct NameSourceCSB-YP607323HIW CSB-EP607323HIW CSB-BP607323HIW CSB-MP607323HIW CSB-EP607323HIW-B Recombinant Human coronavirus HKU1 Nucleoprotein(N)Yeast E.coli Baculovirus Mammalian cell In Vivo Biotinylation in E.coli Spike glycoprotein Proteins for Human coronavirus NL63 (HCoV-NL63) CodeProduct NameSourceCSB-YP747509HIX CSB-EP747509HIX CSB-BP747509HIX CSB-MP747509HIX CSB-EP747509HIX-B Recombinant Human coronavirus NL63 Spike glycoprotein(S) ,partialYeast E.coli Baculovirus Mammalian cell In Vivo Biotinylation in E.coli Spike glycoprotein Proteins for Human coronavirus 229E (HCoV-229E) CodeProduct NameSourceCSB-YP321366HIT CSB-EP321366HIT CSB-BP321366HIT CSB-MP321366HIT CSB-EP321366HIT-B Recombinant Human coronavirus 229E Spike glycoprotein(S) ,partialYeast E.coli Baculovirus Mammalian cell In Vivo Biotinylation in E.coli Spike glycoprotein Proteins for Human Novel Coronavirus (SARS-CoV-2/ 2019-nCoV) CodeProduct NameSourceCSB-MP3324GMYRecombinant Human Novel Coronavirus Spike glycoprotein(S), partialMammalian cellCSB-YP3324GMY1Recombinant Human Novel Coronavirus Spike glycoprotein(S), partialYeastCSB-MP3324GMY1Recombinant Human Novel Coronavirus Spike glycoprotein(S), partialMammalian cellCSB-MP3324GMY1-BRecombinant Human Novel Coronavirus Spike glycoprotein(S), partial,BiotinylatedMammalian cellCSB-MP3324GMY-BRecombinant Human Novel Coronavirus Spike glycoprotein(S), partialMammalian cellCSB-MP3324GMY1(M5)Recombinant Human Novel Coronavirus Spike glycoprotein(S) (V483A), partialMammalian cellCSB-MP3324GMY1(M4)Recombinant Human Novel Coronavirus Spike glycoprotein(S) (G476S), partialMammalian cellCSB-MP3324GMY1(M3)Recombinant Human Novel Coronavirus Spike glycoprotein(S) (N354D,D364Y), partialMammalian cellCSB-MP3324GMY1(M2)Recombinant Human Novel Coronavirus Spike glycoprotein(S) (W436R), partialMammalian cellCSB-MP3324GMY1(M1)Recombinant Human Novel Coronavirus Spike glycoprotein(S) (V367F), partialMammalian cellCSB-MP3324GMY(M1)Recombinant Human Novel Coronavirus Spike glycoprotein(S) (D614G), partialMammalian cellCSB-MP3324GMY(M2)Recombinant Human Novel Coronavirus Spike glycoprotein(S)(N501Y,P681H),partialMammalian cellCSB-MP3324GMY1(M6)Recombinant Human Novel Coronavirus Spike glycoprotein(S) (N501Y),partialMammalian cellCSB-MP3324GMY1(M6)k2Recombinant Human Novel Coronavirus Spike glycoprotein(S) (N501Y),partialMammalian cellSpike glycoprotein Proteins for Human Novel Coronavirus (SARS-CoV-2/ 2019-nCoV) CodeProduct NameSourceCSB-YP3324GMYa4Recombinant Human Novel Coronavirus Spike glycoprotein(S), partialYeastCSB-MP3324GMY1b1Recombinant Human Novel Coronavirus Spike glycoprotein(S), partialMammalian cellSpike glycoprotein Proteins for Homo sapiens (Human) CodeProduct NameSourceCSB-MP348663HQERecombinant Human SARS coronavirus Spike glycoprotein(S),partialMammalian cellSpike glycoprotein Proteins for Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2) CodeProduct NameSourceCSB-YP3324GMY2Recombinant Human Novel Coronavirus Spike glycoprotein(S), partialYeastCSB-MP3324GMY1(M7)Recombinant Human Novel Coronavirus Spike glycoprotein(S) (K417N),partialMammalian cellCSB-MP3324GMY1(M7)h8Recombinant Human Novel Coronavirus Spike glycoprotein(S) (K417N),partialMammalian cellCSB-MP3324GMY1(M8)Recombinant Human Novel Coronavirus Spike glycoprotein(S) (E484K),partialMammalian cellCSB-MP3324GMY1(M8)h8Recombinant Human Novel Coronavirus Spike glycoprotein(S) (E484K),partialMammalian cell

Spike glycoprotein Background SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2), a novel coronavirus found in late 2019, tremendously attracted the attention of global scientific researchers [2]. This newly definite coronavirus is an enveloped RNA virus, and it is zoonotic and can cause severe and atypical pneumonia [2]. One type of spike-like shaped protein on the envelope of the coronavirus is spike glycoproteins. People commonly call it S protein. The S-protein of the coronavirus is the structural protein responsible for the crown-like shape of the CoV viral particles, and "coronavirus" was originally named for this reason. S proteins belong to transmembrane proteins and mediate the viral attachment to host cell, host-virus interaction, and virus entry into the host cell [3][4]. There are two functional subunits in the S protein: S1 subunit responsible for binding to the host cell receptor and S2 subunit for the fusion of the viral and cellular membranes [5][6]. The S2 protein contains the fusion peptide (FP), a second proteolytic site (S2′), followed by an internal fusion peptide (IFP) and two heptad-repeat domains preceding the transmembrane domain (TM). Coronavirus enters cells by viral S glycoprotein-mediated binding to host cells and subsequent fusion of virus and host cell membranes [4]. During infection, the trimetric S-protein of coronavirus is processed at the S1/S2 cleavage site by host cell proteases [7]. S protein is divided into an N-terminal S1-ectodomain that recognizes a cognate cell surface receptor and a C-terminal S2-membrane-anchored protein involved in viral entry after the cleavage or priming [7]. The SARS-CoV S1-protein recognizes the angiotensin-converting enzyme 2 (ACE2) through a conserved Receptor Binding Domain (RBD) [8]. Wan et al. found that several residues among the 14 amino acids in the S1 of SARS-CoV are strictly conserved in 2019-nCoV, suggesting that ACE2 is also the receptor of the newly emerged nCoV [2][9]. The internal fusion peptides (IFPs) of the 2019-nCoV are the same as that of the SARS-CoV, showing characteristics of viral fusion peptides [9]. Alexandra C. Walls et al. identified a peculiar furin-like cleavage site in the spike protein of the SARS-CoV-2, lacking in the other SARS-like CoVs, despite a high similarity with the genome sequence of SARS-CoV and SARS-like CoVs [6]. Berend-Jan Bosch, a coronavirus specialist at Utrecht University in the Netherlands, said that all viral proteins will elicit antibody responses to some extent. Since spike protein is the sole protein on the viral surface responsible for entry into the host cell, it is the main antigen that elicits neutralizing antibodies. Some SARS-CoV-2 S1 protein IgG antibody ELISA kits, therefore, are developed to detect this virus. Spike S2 subunit is more conserved among CoVs and thus plays a role in the cross-reactivity seen when the whole S was used as an antigen. While S1 is more specific than S as an antigen for SARS-CoV-2 serological diagnosis.


17 views0 comments

Comments

bottom of page